During the first month of GLP-1 weight treatment, follow-up focuses on appetite, side effects and how the prescribed plan is working. Weight response varies by medicine and by person.[1]
Appetite and side effects are different observations
Semaglutide reduces calorie intake through effects that are likely related to appetite. Its prescribing information also lists gastrointestinal adverse effects, including nausea, vomiting, diarrhea and constipation.[2]
That means the early experience is worth describing precisely: a change in hunger, a change in meal intake and difficulty tolerating food are different observations. Persistent or severe symptoms should be reported to the prescribing clinician; vomiting or diarrhea can lead to dehydration and kidney injury.[2]
The initial plan is built around tolerability
Approved semaglutide labeling uses a gradual increase during treatment initiation and allows changes when an increase is not tolerated. Any adjustment belongs with the prescribing clinician.[2]
The starting phase differs from longer-term treatment, so year-long study averages do not predict a first-month result.
Look beyond one scale reading
NIDDK describes medication choice and continuation as a balance of benefit, side effects and individual circumstances. Medicines are used alongside nutrition and activity support, and outcomes differ between people.[1]
An early follow-up can therefore address several useful questions: what has changed in appetite and intake, which symptoms have occurred, whether the plan is practical, and what trend is emerging over time.
